Oral Cancer News – Page 141 – The Oral Cancer Foundation News Archive

Bidi smoking causes cancer

Source: www.vancouverdesi.com Author: staff The country’s (India) first such study, using cohort groups, has proven conclusively that smoking bidi (tobacco wrapped in the leaf of the tendu plant) increases the propensity for cancer. P. Jayalekshmi of the Regional Cancer Centre (RCC) here, who led the study on bidi-induced lung, oral, laryngeal and hypopharyngeal cancer, said lung cancer risk among former bidi smokers was higher than in those who never smoked bidis. Separate studies on the impact of bidi smoking on lung and oral cancers, and cancers of larynx and hypopharynx in close to 70,000 men between the age group of 30-84 in Karunagappally in Kollam district shows that bidi is among the most harmful smoking products. “The risk of cancer affecting the cheek (buccal) and lips (labial) showed a nearly four-fold increase in the cohort study covering 66,277 men. “Excessive use of bidis significantly increased the risk associated with cancer of the gum and mouth,” Jayalekshmi said. The mainstream smoke of bidi contains a much higher concentration of carcinogenic hydrocarbons. Bidi smokers also are found to be taking five puffs per minute, compared to two puffs by cigarette smokers in the same time, the study showed. The cohort study on bidi and lung cancer, covering a total of 65,829 men, found that bidi smokers had a 3.9-fold increase in lung cancer incidence, when compared to those who never smoked bidis. The study showed that tongue cancer risk increased significantly among men who smoked bidis for 30 years or longer, and [...]

Oral Cancer Foundation News Team - A2013-03-23T10:28:32-07:00March, 2013|Oral Cancer News|

Noninvasive oral cancer test eases patient fears

Source: www.drbicuspid.com Author: Donna Domino, Features Editor A new, noninvasive cytology test for oral cancer, ClearPrep OC, is being offered free to dentists. The test, aimed at "watch and wait" lesions, is less expensive than biopsies and less frightening for patients, according to Resolution Biomedical, the company that is commercializing it. The chairside oral cancer test -- which can be ordered directly from the company -- is designed to be a diagnostic option for assessing lesions when a biopsy is not warranted or the patient fears getting a biopsy, according to Donald Williams, MD, chief medical officer of Resolution Biomedical. The test involves a cyto-brush sampling method that measures gross changes in the nuclear DNA content of oral epithelial cells, providing information about the precancerous or cancerous state of a lesion, the company explained. The samples are sent to medical testing labs, and the report is sent to the dentist within four to five days, the same time frame as biopsies. Dentists send the samples to the company, which prepares the slides and sends them to labs, which prepare a diagnostic report for the dentists. "It's a way to triage patients where something may be suspicious but the patient is balking about getting a biopsy," Dr. Williams told DrBicuspid.com. "It could be leukoplakia lesions or thrush instead of an indication of a neoplasm. It rules out biopsies without an invasive process." When dentists refer patients to periodontists to get biopsies of suspicious lesions, many patients don't follow through on the [...]

Oral Cancer Foundation News Team - A2013-03-23T10:22:46-07:00March, 2013|Oral Cancer News|

Spike in oral cancers puzzles experts

Source: www.turnto23.com Author: Victoria Colliver/San Francisco Chronicle Christine Schulz has never visited England, but she speaks with the clipped inflection of a vaguely British accent. It's not an affectation but, rather, the mystifying after-effect of an 18-hour surgery she endured in 2009 to remove about half her tongue due to a cancerous growth that had spread to her lymph nodes. Surgeons used skin from her wrist and upper leg to re-create the missing portions of her tongue. Through long term speech therapy, Schulz, 47, of Hollister, Calif., re-learned how to eat and talk with her reconstructed tongue. If she sounds as if she's from a different country, Schulz isn't complaining. "At the moment I woke up from surgery, I realized exactly what a huge deal it was," she said, describing how she had an incision in her throat to allow her to breathe and was prohibited to speak in her earliest days of healing. Oral cancers, which include those of the mouth and tongue, are most common in men over 60 with a long history of smoking or chewing tobacco, often combined with heavy drinking. But in recent years, a spike in the incidence of oral cancers is being attributed to human papilloma virus or HPV. But Schulz's cancer was neither HPV-- nor tobacco-related. That puts her in a camp of fewer than 7 percent of all oral cancers that have no identifiable cause, according to the Oral Cancer Foundation, an advocacy group based in Newport Beach, Calif. "Surprisingly, a [...]

Oral Cancer Foundation News Team - A2013-03-23T10:17:08-07:00March, 2013|Oral Cancer News|

Science: Beef Good, Bacon Not So Bad

Source: motherjones.comBy: Stephanie MencimerDate: March 18, 2013 Note from OCF: While this story is not directly about oral cancer, we included it in our feed to show how studies often do not produce results that are useful or even accurate, as they may contain a great deal if bias in the study design. Poorly designed studies are plentiful even in reputable journals, from institutions with good reputations. A new European study claims an increase in processed-meat consumption raises the risk of early death. But the real news? Red meat won't kill you. Earlier this month, researchers announced the results of a big new nutritional study in Europe that seemed to yield more evidence that processed meats like bacon and sausage can lead to an early grave. The media responded with the usual "Death by Salami" headlines. What news outlets downplayed about the study, though, is that despite their best efforts, the EU researchers couldn't find any evidence that red meat will kill you. In fact, the study shows that not eating red meat is a risk factor for an early demise. After correcting some measurement errors, the researchers in Europe had to conclude that not only was red meat intake "no longer associated with mortality" but "all-cause mortality was higher among participants with very low or no red meat consumption." The government, public health advocates, and the American Heart Association have long warned Americans that overconsumption of red meat can lead to heart disease and other ailments. Yet the scientific evidence supporting [...]

Charlotte Parker2013-03-22T13:01:11-07:00March, 2013|Oral Cancer News|

Decoding the oral leukoplakia/oral cancer link

Source: www.drbicuspid.com Author: DrBicuspid Staff Is there a direct relationship between oral leukoplakia and tobacco and alcohol consumption? Do all oral leukoplakias lead to oral squamous cell carcinoma (OSCC)? Is it possible to detect premalignant oral leukoplakia? These are some of the questions a recent literature review in Oral Diseases attempted to answer (January 11, 2013). A team of researchers from Italy, Spain, the U.K., and the U.S. did a literary search of Medline/PubMed, Embase, and Best Evidence from January 1966 to June 2012. Search terms included leukoplakia, oral leukoplakia, preneoplastic oral, precancerous oral, oral precancerous, oral dysplasia, oral mucosal lesion, proliferative verrucous leukoplakia, multifocal leukoplakias, tobacco, and alcohol. The searches were designed to help the study authors address four key questions: 1.Do tobacco and alcohol cause oral leukoplakias? 2.What percentage of oral leukoplakias evolve into OSCC? 3.Can practitioners distinguish between premalignant and innocent oral leukoplakias? 4.Is proliferative verrucous leukoplakia (PVL) a specific entity or just a form of multifocal leukoplakia? For the purposes of this study, the term oral leukoplakia was used to recognize "predominantly white plaques of questionable risk, having excluded (other) known diseases or disorders that carry no increased risk of cancer." Tobacco, alcohol, and oral leukoplakia Although oral leukoplakia is generally considered one of the primary clinical precursors of OSCC, "the role of alcohol and smoking in this disorder has never been thoroughly assessed," the researchers wrote. "Existing evidence suggests that tobacco and alcohol could be associated with at least a subset of [oral leukoplakia]." It [...]

Oral Cancer Foundation News Team - A2013-03-18T11:47:44-07:00March, 2013|Oral Cancer News|

Researchers document molecular tumor subtypes of head and neck cancer

Source: www.oncologynurseadvisor.com Author: Kathy Boltz, PhD Head and neck squamous cell carcinoma (HNSCC) is the seventh most common form of cancer in the United States. However, other than an association with the human papillomavirus (HPV), no validated molecular profile of the disease has been established. By analyzing data from DNA microarrays, a study has confirmed the presence of four molecular classes of the disease. Also, previous results have been extended by suggesting an underlying connection between the molecular classes and observed genomic events, some of which affect cancer genes. This study also demonstrated the clinical relevance of the classes and certain genomic events, paving the way for further studies and possible targeted therapies. "Cancer is a disease caused by alteration in the DNA and RNA molecules of tumors. A cancer results when broken molecules initiate a cascade of abnormal signals that ultimately results in abnormal growth and spread of tissues that should be under tight control within the body,” said Neil Hayes, MD, MPH, of the University of North Carolina Lineberger Comprehensive Cancer Center and of The Cancer Genome Atlas. "However, most common tumors, including head and neck cancer, have relatively little information in the public record as to how these signals coordinate to create different patterns of abnormalities. This study is among the largest ever published to document reproducible molecular tumor subtypes. Subtypes, such as those we describe, represent attractive models to understand and attack cancers for treatment and prognosis." The team analyzed a set of nearly 140 HNSCC [...]

Oral Cancer Foundation News Team - A2013-03-12T07:08:52-07:00March, 2013|Oral Cancer News|

Are combination therapies effective for advanced SCCHN?

Source: Author: DrBicuspid Staff In a recent study, researchers from the University of North Carolina (UNC) Lineberger Comprehensive Cancer Center examined whether the addition of multiple drugs to radiation therapy is superior to the current standard of care therapy with one drug and radiation for locally advanced squamous cell carcinoma of the head and neck (SCCHN). Their data, published in the Journal of Clinical Oncology, suggests that it does not (March 4, 2013). Standard therapy for SCCHN is a combination of the drug cisplatin and radiotherapy. This clinical trial compared this combination to the combination with the addition of a small-molecule inhibitor of the epidermal growth factor receptor (EGFR) erlotinib. For the study, 204 patients with locally advanced SCCHN were recruited between December 2006 and October 2011. Participants were assigned to receive either cisplatin and radiotherapy or the same chemoradiotherapy with erlotinab. EGFR is a therapeutic target for this type of cancer, and at least one other EGFR is approved for multiple uses in treating head and neck cancer, including in combination with radiation. To date, no data have been published on the use of EGFR inhibitors in combination with chemotherapy and radiation. The goal of the current study was to determine if adding EGRF inhibition improved efficacy when combined with standard of care radiation. Unfortunately, the researchers found that the addition of EGRF did not improve clinical response rate or progression-free survival. "There has been great enthusiasm and some confusion about the combinations of chemotherapy and biologic therapy such [...]

Oral Cancer Foundation News Team - A2013-03-12T07:00:53-07:00March, 2013|Oral Cancer News|

Regular dental checkups key to early detection of oral cancer

Source: www.dentistryiq.com Author: Mark Newman, News Staff Julie DiNardo knew something wasn't right. The long-time Mountain registered dental hygienist was chatting with Pino, her husband of 23 years, at the breakfast table back in April 2011 when she became concerned about a lack of symmetry on Pino's face. "He looked a little off on one side of his throat," said Julie, who has been screening people for oral cancer for more than a quarter-century. As she has been trained to do, Julie began to feel her husband's neck, her fingers pushing down gently, but firmly in a number of places. Little did she know, her many years of encouraging the public to get annual oral check-ups was about to hit home. Under Pino's right ear, along the jaw line, Julie discovered something she described as feeling like a fish. Her heart skipped a beat. "When you've felt thousands of necks and you've felt thousands of normals, when an abnormal comes up, you know it," Julie said. While dozens of worrisome thoughts raced through her mind at the time, the mother of four told her husband to get the lump checked out at their family doctor right away. The family doctor couldn't find anything and sent Pino home with antibiotics in case there was some inflammation. Julie said she insisted her husband see a specialist and Pino was examined by an ear, nose and throat doctor who was also unable to find anything. The specialist did send Pino for an ultrasound [...]

Oral Cancer Foundation News Team - A2013-03-12T06:55:37-07:00March, 2013|Oral Cancer News|

Targeted Drugs No Help in Head and Neck Cancer

Source: medpagetoday.comAuthor: Charles Bankhead, Staff Writer, MedPage TodayDate: March 05, 2013 The addition of targeted agents to standard chemotherapy failed to improve efficacy in two different trials of advanced head and neck cancer. In one trial, patients given gefitinib (Iressa) in addition to docetaxel lived about a month longer than those who received docetaxel plus placebo. In the other trial, adding erlotinib (Tarceva) to cisplatin-based chemoradiation did not improve response rate or progression-free survival. However, neither regimen was associated with increased toxicity compared with standard chemotherapy, investigators reported online in the Journal of Clinical Oncology. Noting the lack of useful biomarkers to guide the use of targeted agents, the authors of an accompanying editorial said that experience to date suggests current strategies amount to "skimming the surface of a problem that is exceedingly complex." "It is unlikely that genomic sequencing alone will represent a panacea to the therapeutic challenges in squamous cell carcinoma of the head and neck," said Aaron R. Hansen, MBBS, and Lillian L. Siu, MD, of Princess Margaret Cancer Center in Toronto. "Comprehensive characterization that encompasses a broader omics-based molecular evaluation, as well as immune function assessments, is urgently needed." The rationale for the gefitinib and erlotinib trials came from evidence that the drugs targeting epidermal growth factor receptors (EGFR) have synergism with conventional chemotherapeutic agents, have radiosensitizing properties, and have demonstrated modest activity as monotherapy in some clinical studies. Cetuximab (Erbitux), another EGFR inhibitor, has been approved for use with radiation therapy or as monotherapy [...]

Charlotte Parker2013-03-07T14:25:20-07:00March, 2013|Oral Cancer News|

Five genetic subgroups revealed in head and neck tumor analysis

Source: www.onclive.com Author: Ben Leach Oncologists who treat patients with head and neck cancer are aware that those whose disease has been caused by human papillomavirus (HPV) have significantly better outcomes than those whose disease is caused by other factors such as smoking. However, new research suggests that there may be five distinct subgroups in which specific genetic profiles may be utilized to guide treatment decisions in patients. “Currently, we treat all patients with head and neck cancer in essentially the same way,” said Ezra E. W. Cohen, MD, co-director of the Head and Neck Cancer Program at the University of Chicago Medical Center. “But we do know that the prognosis for patients who are HPV-positive is much better.” To determine whether patients’ genetic profiles differed, Cohen and his colleagues at the University of Chicago, led by researcher Tanguy Seiwert, MD, took approximately 130 tumor samples from patients with stage IV squamous cell carcinoma of the head and neck and performed gene expression (mRNA) analysis. The samples were gathered before patients received therapy, and all of the participants subsequently were treated with a 5-fluorouracil, hydroxyurea, and concurrent radiation (FHX)-based regimen. This way, the researchers could determine the outcome as a function of gene expression in the groups identified through the analysis, since patients received the same treatment across all the subgroups eventually identified. Cohen said that patients were enrolled regardless of whether they were HPV-positive or HPV-negative. Based on these findings, the University of Chicago team was able to classify [...]

Oral Cancer Foundation News Team - A2013-03-01T15:37:52-07:00March, 2013|Oral Cancer News|